AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,336,895 | -9.1% | 54,016 | +4.0% | 0.00% | – |
Q2 2023 | $1,471,025 | +31.6% | 51,943 | +6.7% | 0.00% | – |
Q1 2023 | $1,117,721 | -16.0% | 48,660 | +2.7% | 0.00% | -100.0% |
Q4 2022 | $1,330,906 | +1.8% | 47,397 | +2.6% | 0.00% | 0.0% |
Q3 2022 | $1,307,000 | +25.2% | 46,193 | -1.9% | 0.00% | – |
Q2 2022 | $1,044,000 | -25.6% | 47,094 | -2.3% | 0.00% | – |
Q1 2022 | $1,403,000 | -11.9% | 48,199 | -0.5% | 0.00% | – |
Q4 2021 | $1,593,000 | -30.1% | 48,459 | -1.8% | 0.00% | -100.0% |
Q3 2021 | $2,278,000 | +8.0% | 49,353 | +28.9% | 0.00% | 0.0% |
Q2 2021 | $2,110,000 | +10.2% | 38,284 | +3.2% | 0.00% | 0.0% |
Q1 2021 | $1,915,000 | +39.0% | 37,100 | +16.7% | 0.00% | 0.0% |
Q4 2020 | $1,378,000 | -16.5% | 31,792 | -32.5% | 0.00% | 0.0% |
Q3 2020 | $1,650,000 | -34.8% | 47,124 | -0.4% | 0.00% | 0.0% |
Q2 2020 | $2,531,000 | +68.3% | 47,328 | +11.7% | 0.00% | 0.0% |
Q1 2020 | $1,504,000 | -16.3% | 42,383 | +12.7% | 0.00% | 0.0% |
Q4 2019 | $1,796,000 | +52.6% | 37,621 | +3.5% | 0.00% | 0.0% |
Q3 2019 | $1,177,000 | -24.0% | 36,336 | +17.0% | 0.00% | 0.0% |
Q2 2019 | $1,549,000 | -24.8% | 31,049 | +1.7% | 0.00% | 0.0% |
Q1 2019 | $2,059,000 | +49.2% | 30,529 | +2.0% | 0.00% | 0.0% |
Q4 2018 | $1,380,000 | -32.4% | 29,924 | +13.1% | 0.00% | 0.0% |
Q3 2018 | $2,041,000 | +2.0% | 26,464 | +11.5% | 0.00% | -50.0% |
Q2 2018 | $2,000,000 | -0.1% | 23,745 | -3.0% | 0.00% | 0.0% |
Q1 2018 | $2,002,000 | -75.2% | 24,478 | -82.7% | 0.00% | -66.7% |
Q4 2017 | $8,085,000 | +645.8% | 141,409 | +770.7% | 0.01% | +500.0% |
Q3 2017 | $1,084,000 | +68.3% | 16,241 | +29.8% | 0.00% | 0.0% |
Q2 2017 | $644,000 | +10.1% | 12,517 | +25.0% | 0.00% | – |
Q1 2017 | $585,000 | +333.3% | 10,011 | +209.2% | 0.00% | – |
Q4 2016 | $135,000 | +51.7% | 3,238 | +92.7% | 0.00% | – |
Q3 2016 | $89,000 | +27.1% | 1,680 | 0.0% | 0.00% | – |
Q2 2016 | $70,000 | +7.7% | 1,680 | +5.0% | 0.00% | – |
Q1 2016 | $65,000 | -35.0% | 1,600 | +4.1% | 0.00% | – |
Q4 2015 | $100,000 | +81.8% | 1,537 | +96.5% | 0.00% | – |
Q3 2015 | $55,000 | -20.3% | 782 | +25.9% | 0.00% | – |
Q2 2015 | $69,000 | -72.5% | 621 | -76.0% | 0.00% | – |
Q1 2015 | $251,000 | +2.4% | 2,584 | +20.2% | 0.00% | – |
Q4 2014 | $245,000 | +34.6% | 2,150 | -24.7% | 0.00% | – |
Q3 2014 | $182,000 | – | 2,854 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Ventures 2007 General Partner LLC | 1,930,369 | $80,873,000 | 75.24% |
Casdin Capital, LLC | 187,500 | $7,855,000 | 7.82% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 40,000 | $1,676,000 | 4.87% |
BB BIOTECH AG | 2,363,321 | $99,011,000 | 3.91% |
AlpInvest Partners B.V. | 30,000 | $1,257,000 | 2.49% |
Opaleye Management Inc. | 85,000 | $3,561,000 | 2.38% |
Opus Point Partners Management, LLC | 43,295 | $1,814,000 | 1.75% |
Clarius Group, LLC | 47,666 | $1,997,000 | 1.06% |
CAPITAL INTERNATIONAL LTD /CA/ | 260,600 | $10,918,000 | 0.79% |
Eventide Asset Management | 300,800 | $12,602,000 | 0.77% |